CoChat

Treatment of Myeloma: Cure vs Control

Open access
Rajkumar, S. Vincent · 2008 · Mayo Clinic Proceedings
Cited by 73

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

Although not often openly acknowledged, “cure versus control” is the dominant philosophical difference behind many of the strategies, trials, and debates related to the management of myeloma. Should we treat patients with myeloma with multidrug, multitransplant combinations with the goal of potentially curing a subset of patients, recognizing that the risk of adverse events and effect on quality of life will be substantial? Or should we address myeloma as a chronic incurable condition with the goal of disease control, using the least toxic regimens, emphasizing a balance between efficacy and quality of life, and reserving more aggressive therapy for later? To be sure, if cure were known to be possible (with a reasonable probability) in myeloma, it would undoubtedly be the preferred therapeutic goal of most patients and physicians. But this is not the case. Myeloma is generally not considered a curable disease; however, new definitions of cure have been suggested, including operational cure, which is defined as a sustained complete response (CR) for a prolonged period. (1,2) Cure versus control is debated because the strategies currently being tested are not truly curative but rather are intended to maximize response rates in the hope that they will translate into an operational cure for a subset of patients. For decades, the treatment of myeloma was restricted to conventional chemotherapy with alkylators and corticosteroids, and the question of cure versus control never arose. The response rate with alkylators and corticosteroids was only about 50%, and CR (3,4) was rare. Cure was never a goal of therapy because it was assumed to be unattainable. Instead, the goal was to control the disease as much as possible, providing the best quality of life to the patient for the longest duration by judicious, intermittent use of the 2 available classes of active chemotherapeutic agents. In the 1990s, high-dose therapy with autologous stem cell transplant (ASCT) became part of standard practice when it was found to prolong survival compared with conventional chemotherapy. (5-7) Subsequently, bisphosphonates were found to be effective in decreasing the incidence of bone lesions. (8,9) In the past decade, thalidomide, (10) bortezomib (11-13) and lenalidomide (14,15) emerged as effective agents for the treatment of myeloma, producing spectacular results in combination with other known agents in terms of response rate, CR rate, progression-free survival (PFS), and (more recently) overall survival. Numerous combinations have been developed, resulting in a veritable alphabet soup of clinical trials (16) and drug combinations are vying with each other for the highest response rate (and prominence). (17,18) The results obtained with new combinations have indeed been remarkable and have prompted a relatively new philosophy of treating myeloma with the goal of potential cure rather than disease control. These philosophical differences underpin the various clinically relevant debates regarding myeloma currently confronting patients and

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4065/83.10.1142

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 12 references

Research works printed but not linked: 52

  1. Sirohi, 2001, International myeloma grand round, Lancet Oncol, 2, 571, 10.1016/S1470-2045(01)00491-0 · doi:10.1016/s1470-2045(01)00491-0
  2. Mehta, 2007, High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years, Bone Marrow Transplant, 40, 1101, 10.1038/sj.bmt.1705799 · DOI
  3. Anderson, 2008, Clinically relevant end points and new drug approvals for myeloma, Leukemia, 22, 231, 10.1038/sj.leu.2405016 · DOI · Paper page
  4. Barlogie, 1997, Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma, Blood, 89, 789, 10.1182/blood.V89.3.789 · DOI · Paper page
  5. Lacy, 2006, Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma, Mayo Clin Proc, 81, 1047, 10.4065/81.8.1047 · DOI · Paper page
  6. Durie, 2007, Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [letter], Mayo Clin Proc, 82, 516, 10.4065/82.4.516 · DOI
  7. Richardson, 2005, Bortezomib or high-dose dexamethasone for relapsed multiple myeloma, N Engl J Med, 352, 2487, 10.1056/NEJMoa043445 · DOI · Paper page
  8. Cavo, 2006, Proteasome inhibitor bortezomib for the treatment of multiple myeloma, Leukemia, 20, 1341, 10.1038/sj.leu.2404278 · DOI
  9. Hussein, 2006, Phase 2 study of pegylated liposomal doxorubicin, vincristine, reduced schedule dexamethasone and thalidomide (DVd-T) in newly diagnosed and relapsed/refractory multiple myeloma, Mayo Clin Proc, 81, 889, 10.4065/81.7.889 · DOI
  10. Dispenzieri, 2007, Treatment of newly diagnosed multiple myeloma based on Mayo stratification of myeloma and risk-adapted therapy (mSMART): consensus statement, Mayo Clin Proc, 82, 323, 10.1016/S0025-6196(11)61029-X · DOI · Paper page
  11. Lacy, 2006, Multiple myeloma: new options, new challenges [editorial], Mayo Clin Proc, 81, 877, 10.4065/81.7.877 · DOI
  12. Lonial, 2007, Designing risk-adapted therapy for multiple myeloma: the Mayo perspective [editorial], Mayo Clin Proc, 82, 279, 10.1016/S0025-6196(11)61022-7 · DOI
  13. Adjei, 2007, Cancer symposium for the practitioner: introduction to solid tumors, Mayo Clin Proc, 82, 107, 10.1016/S0025-6196(11)60973-7 · DOI
  14. Tefferi, 2006, Atypical myeloproliferative disorders: diagnosis and management, Mayo Clin Proc, 81, 553, 10.4065/81.4.553 · DOI
  15. Quintas-Cardama, 2006, Chronic myeloid leukemia: diagnosis and treatment, Mayo Clin Proc, 81, 973, 10.4065/81.7.973 · DOI · Paper page
  16. Steensma, 2006, The myelodysplastic syndromes: diagnosis and treatment, Mayo Clin Proc, 81, 104, 10.4065/81.1.104 · DOI · Paper page
  17. Yee, 2006, Chronic lymphocytic leukemia: diagnosis and treatment, Mayo Clin Proc, 81, 1105, 10.4065/81.8.1105 · DOI
  18. Mauro, 2006, Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used?, Mayo Clin Proc, 81, 404, 10.4065/81.3.404 · DOI
  19. Wolanskyj, 2006, Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors, Mayo Clin Proc, 81, 159, 10.4065/81.2.159 · DOI · Paper page
  20. Aletti, 2007, Current management strategies for ovarian cancer, Mayo Clin Proc, 82, 751, 10.1016/S0025-6196(11)61196-8 · DOI · Paper page
  21. Steensma, 2007, Anemia in the elderly: how should we define it, when does it matter, and what can be done?, Mayo Clin Proc, 82, 958, 10.4065/82.8.958 · DOI
  22. Facon, 2007, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial, Lancet, 370, 1209, 10.1016/S0140-6736(07)61537-2 · DOI · Paper page
  23. Barlogie, 2006, Thalidomide and hematopoietic-cell transplantation for multiple myeloma, N Engl J Med, 354, 1021, 10.1056/NEJMoa053583 · DOI · Paper page
  24. Landgren, 2007, Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana, Mayo Clin Proc, 82, 1468, 10.4065/82.12.1468 · doi:10.4065/82.12.1468
  25. Iwanaga, 2007, Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan, Mayo Clin Proc, 82, 1474, 10.4065/82.12.1474 · doi:10.4065/82.12.1474
  26. Rajkumar, 2006, Monoclonal gammopathy of undetermined significance, Waldenström macroglobulinemia, AL amyloidosis, and related plasma cell disorders: diagnosis and treatment, Mayo Clin Proc, 81, 693, 10.4065/81.5.693 · DOI · Paper page
  27. Zhan, 2006, The role of cytogenetics in myeloma [editorial], Leukemia, 20, 1484, 10.1038/sj.leu.2404330 · DOI
  28. Chiecchio, 2006, Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma, Leukemia, 20, 1610, 10.1038/sj.leu.2404304 · DOI · Paper page
  29. Gutierrez, 2007, Leukemia, 21, 143, 10.1038/sj.leu.2404413 · DOI · Paper page
  30. Chng, 2006, Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations, Leukemia, 20, 807, 10.1038/sj.leu.2404172 · DOI
  31. Stewart, 2007, A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy, Leukemia, 21, 529, 10.1038/sj.leu.2404516 · DOI · Paper page
  32. Haessler, 2007, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling, Clin Cancer Res, 13, 7073, 10.1158/1078-0432.CCR-07-0527 · DOI · Paper page
  33. Gertz, 2008, Autologous stem cell transplant in 716 patients with multiple myeloma: low treatment-related mortality, feasibility of outpatient transplant, and effect of a multidisciplinary quality initiative, Mayo Clin Proc, 83, 1131, 10.4065/83.10.1131 · DOI
  34. Barlogie, 1999, Total therapy with tandem transplants for newly diagnosed multiple myeloma, Blood, 93, 55, 10.1182/blood.V93.1.55 · DOI · Paper page
  35. Attal, 2002, Double autologous transplantation improves survival of multiple myeloma patients: final analysis of a prospective randomized study of the “Intergroupe Francophone du Myelome” (IFM 94) [abstract 7], Blood, 100, 5a
  36. Mihelic, 2007, Maintenance therapy in multiple myeloma, Leukemia, 21, 1150, 10.1038/sj.leu.2404633 · DOI
  37. Lacy, 2007, Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma, Mayo Clin Proc, 82, 1179, 10.4065/82.10.1179 · DOI
  38. Facon, 1996, Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM): preliminary results of a prospective randomized trial (CIAM protocol) [abstract 2729], Blood, 88, 685a
  39. Barlogie, 2003, Blood, 102, 42a
  40. Cavo, 2004, Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma [abstract A536], Blood, 104, 155a
  41. Fermand, 2003, Hematol J, 4, S59
  42. Goldschmidt, 2003, Single vs. tandem autolgous transplantation in multiple myeloma: the GMMG experience [abstract], Hematol J, 4, S61
  43. Bladé, 2003, High-dose therapy autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy: definitive results from PETHEMA after a median follow-up of 66 months [abstract 137], Blood, 102, 42a
  44. Rajkumar, 1999, Autologous stem cell transplantation for relapsed and primary refractory myeloma, Bone Marrow Transplant, 23, 1267, 10.1038/sj.bmt.1701805 · DOI
  45. Bladé, 2000, Treatment approaches for relapsing and refractory multiple myeloma, Acta Oncol, 39, 843, 10.1080/028418600750063604 · DOI · Paper page
  46. Bensinger, 2006, The current status of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma, Leukemia, 20, 1683, 10.1038/sj.leu.2404333 · DOI
  47. Crawley, 2005, Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT, Blood, 105, 4532, 10.1182/blood-2004-06-2387 · DOI · Paper page
  48. Garban, 2006, Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, Blood, 107, 3474, 10.1182/blood-2005-09-3869 · DOI · Paper page
  49. Haessler, 2007, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling, Clin Cancer Res, 13, 7073, 10.1158/1078-0432.CCR-07-0527 · DOI · Paper page
  50. Jagannath, 2007, Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials, Leukemia, 21, 151, 10.1038/sj.leu.2404442 · DOI · Paper page
  51. Sagaster, 2007, Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion, Leukemia, 21, 164, 10.1038/sj.leu.2404459 · DOI
  52. Moreau, 2007, Heterogeneity of t(4;14) in multiple myeloma: long-term follow-up of 100 cases treated with tandem transplantation in IFM99 trials, Leukemia, 21, 2020, 10.1038/sj.leu.2404832 · DOI

Cited by

Metadata

Authors
Rajkumar, S. V.
Venue
Mayo Clinic Proceedings
Publisher
Elsevier BV
Published
2008-10
Volume
83
Issue
10
Pages
1142-1145
ISSN
0025-6196 (ISSN-L)
OpenAlex
W2169493090
Cited by
73
References
12
FWCI
4.20
Type
journal article
Language
en
Open access
green
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.